All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
The phase III ALLG BM12 CAST trial: GvHD prophylaxis with PTCy + CsA
Graft-versus-host disease (GvHD) remains a significant challenge despite advances in prophylactic treatments. The current standard GvHD prophylaxis treatment is cyclosporin A (CsA) or tacrolimus + methotrexate (MTX) or mycophenolate mofetil (MMF). During the European Hematology Association (EHA) 2025 Congress, David Curtis presented findings from the phase III ALLG BM12 CAST trial (ACTRN12618000505202) assessing the safety and efficacy of post-transplant cyclophosphamide (PTCy) + CsA vs CsA + MTX in patients undergoing allogeneic hematopoietic stem cell transplantation.1 The findings were recently published in The New England Journal of Medicine.2 Patients diagnosed with acute myeloid leukemia or acute lymphoblastic leukemia in complete remission 1 or 2 or myelodysplastic leukemia receiving peripheral blood stem cells from a matched sibling donor in a myeloablative or reduced-intensity chemotherapy setting were included (N = 134). Eligible patients were randomized 1:1 to receive PTCy + CsA (n = 66) or CsA + MTX (n = 68). The primary endpoint was GvHD-free, relapse-free survival. Key secondary endpoints included incidence of acute and chronic GvHD, engraftment, non-relapse mortality, and adverse events. Relapse-free survival was assessed in a post hoc exploratory analysis.1,2
|
Key learnings |
The 3-year GRFS was significantly higher in the PTCy + CsA vs CsA + MTX group (49% vs 14%; HR, 0.42; p < 0.001). |
PTCy + CsA resulted in a significantly higher 2-year RFS rate (74% vs 59%; HR, 0.55; p = 0.045) and a lower CI of Grade 3–4 aGvHD (p = 0.032) and moderate-to-severe cGvHD (p = 0.033) than CsA + MTX. |
PTCy + CsA was well tolerated; the only early toxicity was delayed platelet engraftment compared with CsA + MTX (median time to engraftment was 22 vs 18 days, respectively). Incidence of Grade ≥3 AEs in the first 100 days was lower with PTCy + CsA vs CsA + MTX (20% vs 32%). |
PTCy + CsA was superior compared with CsA + MTX in improving GRFS, with a favorable safety profile. It has the potential to offer a more effective, simpler, and more tolerable alternative to standard GvHD prophylaxis in patients with high-risk blood malignancies in low-resource centers. |
AE, adverse event; aGvHD, acute graft-versus-host disease; ALLG, Australian Leukemia & Lymphoma Group; CI, cumulative incidence; cGvHD, chronic graft-versus-host disease; CsA, cyclosporin A; GvHD, graft-versus-host disease; GRFS, graft-versus-host-disease-free, relapse-free survival; HR, hazard ratio; MMF, mycophenolate mofetil; MTX, methotrexate; PTCy, post-transplant cyclophosphamide; RFS, relapse-free survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?
